New drugs for chemotherapy-induced nausea and vomiting: Focus on palonosetron

Expert Opinion on Drug Metabolism and Toxicology

Volumn 1, Issue 1, 2005, Pages 143-149

  Tonini, Giuseppe ^a   Vincenzi, Bruno ^a   Daniele, Santini ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

antiemetics; chemotherapy; nausea; palonosetron; vomiting

Indexed keywords

ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE; NEW DRUG; PALONOSETRON; QUINUCLIDINE DERIVATIVE;

ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; HUMAN; NAUSEA; REVIEW; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUGS, INVESTIGATIONAL; HUMANS; ISOQUINOLINES; NAUSEA; QUINUCLIDINES; VOMITING;

EID: 33748373643     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.1.1.143     Document Type: Review

References (29)

1. HESKETH PJ: Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists. Support. Care Cancer (1994) 2:286-292.
2. HESKETH PJ: Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. (2000) 18:163-173. (Pubitemid 30118410)
3. IOANNIDIS JP, HESKETH PJ, LAU J: Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J. Clin. Oncol. (2000) 18:3409-3422.
4. GRALLA RJ, OSOBA D, KRIS MG et al.: Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. American Society of Clinical Oncology. J. Clin. Oncol. (1999) 17:2871-2894.
5. MASCC COOPERATIVE GROUP: Prevention of chemotherapy- and radiotherapy-induced emesis results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann. Oncol. (1998) 9:811-819.
6. GRUNBERG SM, DEUSON RR, MAVROS P et al.: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer (2004) 100:2261-2268. (Pubitemid 38580348)
7. ALOXI. US approved Prescribing Information (PI).
8. STOLTZ R, PARISI S, SHAH A, MACCIOCCHI A: Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. Biopharm. Drug Dispos. (2004) 25:329-337. (Pubitemid 39534438)
9. Zofran® [package insert]. Research Triangle Park, NC: GlaxoSmithKline (2002).
10. REITH MK, SPROLES GD, CHENG LK: Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist. Drug. Metab. Dispos. (1995) 23:806-812.
11. TONINI G: Palonosetron: a viewpoint by Giuseppe Tonini. Drugs (2004) 64:1133-1134.
12. STOLTZ R, CYONG J, SHAH A, PARISI S: Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J. Clin. Pharm. (2004) 44:520-531. (Pubitemid 38509721)
13. EISENBERG P, MACKINTOSH FR, RITCH P, CORNETT PA, MACCIOCCHI A: Efficacy, safety and parmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann. Oncol. (2004) 15:330-337. (Pubitemid 38262636)
14. HUNT TL, SHAH A, GALLAGHER S: Repeated daily intravenous (IV) dosing of palonosetron (PALO), a novel 5-HT3 receptor antagonist, is safe and shows predictable pharmacokinetics (PK) [abstract]. Support. Care Cancer. (2004) 12:A373.
15. HUNT TL, GALLAGHER SC, CULLEN MT, SHAH AK: Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. J. Clin. Pharmacol. (2005) 45(5):589-596. (Pubitemid 40562950)
16. SHAH AK, GALLAGHER SC, LATIMER L, CULLEN MT, HUNT TL: Lack of effect of aprepitant (APR) on the pharmacokinetics (PK) and safety of palonosetron (PALO) [abstract]. Clin. Pharmacol. Ther. (2004) 75(2):A78.
17. SHAH AK, HUNT TL, GALLAGHER SC, CULLEN MT Jr: Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr. Med. Res. Opin. (2005) 45(5):589-596. (Pubitemid 40562950)
18. CANTOREGGI S, PARISI S, VAN LAAR E et al.: Palonosetron, a new 5HT3 antagonist does not alter antitumor efficacy of various chemotherapeutics in tumor bearing mice [abstract]. Clin. Cancer Res. (2003) 9:S6254.
19. TRISSEL LA, ZHANG Y: Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann. Pharmacother. (2005) 39:280-283. (Pubitemid 40165218)
20. XU QA, TRISSEL LA: Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am. J. Health. Syst. Pharm. (2004) 61:1596-1598. (Pubitemid 39481402)
21. TRISSEL LA, XU QA: Physical and chemical stability of palonosetron HCl in 4 infusion solutions. Ann. Pharmacother. (2004) 38:1608-1611. (Pubitemid 39297755)
22. TAVORATH R, HESKETH PJ: Drug treatment of chemotherapy-induced delayed emesis. Drugs (1996) 52:639-648. (Pubitemid 26382184)
23. EISENBERG P, FIGUEROA-VADILLO J, ZAMORA R et al., 99 - 04 PALONOSETRON STUDY GROUP: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor anagonist: results of a Phase III, single-dose trial versus dolasetron. Cancer (2003) 98:2473-2482. (Pubitemid 37466663)
24. GRALLA R, LICHINITSER M, VAN DER VEGT S et al.: Palonosetron improves prevention of chemotherapyinduced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. (2003) 14:1570-1577. (Pubitemid 37304615)
25. AAPRO MS, BERTOLI L, LORDICK F et al.: Paolonsetron (PALO) is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Support. Care Cancer. (2003) 11:A17.
26. RUBENSTEIN EB, GRALLA RJ, EISENBERG P et al.: Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute & delayed chemotherapy-induced nausea and vomiting (CINV): combined results of two Phase III trials. Proc. Am. Soc. Clin. Oncol. (2003) 22:A729.
27. GROTE T, HAJDENBERG J, CARTMELL A et al.: Palonosetron (PALO) plus aprepitant (APREP) and dexamethasone (DEX) for the prevention of chemotherapy-induced nausea and vomiting (CINV) after emetogenic chemotherapy (CT). Proc. Am. Soc. Clin. Oncol. (2004) 23:A790.
28. EGLEN RM, LEE CH, SMITH WL et al.: Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br. J. Pharmacol. (1995) 114(4):860-866.
29. SIDDIQUI MA, SCOTT LJ: Palonosetron. Drugs (2004) 64:1125-1132. (Pubitemid 38736896)